The Clinical Significance of IGF-1R and Relationship with Epstein–Barr Virus Markers: LMP1 and EBERs in Tunisian Patients with Nasopharyngeal Carcinoma
Restricted accessResearch articleFirst published online October, 2020
The Clinical Significance of IGF-1R and Relationship with Epstein–Barr Virus Markers: LMP1 and EBERs in Tunisian Patients with Nasopharyngeal Carcinoma
Tunisia is in the endemic area of nasopharyngeal carcinoma. Epstein–Barr virus (EBV) based assays have been commonly used as standard markers for screening and monitoring the disease. So, it is very important to find novel factors for the early diagnostic and prognostic evaluation of this cancer. The aim of the study was to evaluate the expression of IGF-1R (Insulin Growth Factor Receptor 1), LMP 1 (Latent Membrane Protein 1) and EBERs (EBV encoded RNAs) in order to determine their correlation with clinicopathologic parameters and survival rates in patients with nasopharyngeal carcinoma (NPC). We also looked for the relationship between these biomarkers.
Methods:
IGF-1R and LMP1 expression was performed by means of immunohistochemical method and EBERs were detected using in situ hybridization of paraffin embedded tumor tissues of 94 patients with nasopharyngeal carcinoma and 45 non-cancerous nasopharyngeal mucosa samples.
Results:
Our findings demonstrated that IGF-1R was over expressed in 47.87% of NPC patients and only in 2.22% of controls. Positive LMP1 expression was detected in 56.38% of NPC patients and all NPC patients were positive for the EBV-encoded RNAs staining. A statistically significant positive correlation was observed between IGF-1R expression and the tumor size (P < .001). Kaplan–Meier survival curves showed that NPC patients with a strong IGF-1R expression level have shorter median and 5-year Overall Survival than those with weak expression rates (100.15 vs 102.68 months, P = .08). In addition, median and 5-year Disease-Free Survival was significantly lower in the LMP1 positive NPC patients than in the LMP1 negative ones (53.38 vs 93.37 months, P = .03). Moreover, LMP1 expression correlated strongly with IGF-1R expression (P = .018). The relationship between these two biomarkers could influence patient survival.
Conclusion:
IGF1-R and LMP1 could be valuable prognostic markers in Tunisian NPC patients.
McDermottALDuttSNWatkinsonJC. The aetiology of nasopharyngeal carcinoma. Clin Otolaryngol Allied Sci. 2001;26(2):82-92.
2.
ChienYCChenJYLiuMY, et al. Serologic markers of Epstein–Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med. 2001;345(26):1877-1882.
3.
DufournyBAlblasJTeeffelenHA, et al. Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase. J Biol Chem. 1997;272(49):31163-31171.
4.
DziadziuszkoRCamidgeDRHirschFR. The insulin-like growth factor pathway in lung cancer. J Thorac Oncol. 2008;3(8):815-818.
5.
LarssonOGirnitaA. Role of insulin-like growth factor 1 receptor signalling in cancer. Br J Cancer. 2005;92(12):2097-2101.
6.
KhandwalaHMMcCutcheonIEFlyvbjergA, et al. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev. 2000;21(3):215-244.
7.
AbeSFunatoTTakahashiS, et al. Increased expression of insulin-like growth factor I is associated with Ara-C resistance in leukemia. Tohoku J Exp Med. 2006;209(3):217-228.
8.
ImsumranAAdachiYYamamotoHLiR, et al. Insulin-like growth factor-I receptor as a marker for prognosis and a therapeutic target in human esophageal squamous cell carcinoma. Carcinogenesis. 2007;28(5):947-956.
9.
MaWLiWFanQXWangLXWangRLLuSX. Expression of IGF-1R in esophageal squamous cell carcinoma and the effect of its silencing by siRNA on the proliferation of esophageal cancer EC9706 cells in vitro. Zhonghua Zhong Liu Za Zhi. 2011;33(8):609-612.
10.
DricuAKanterLWangM, et al. Expression of the insulin-like growth factor 1 receptor (IGF-1R) in breast cancer cells: evidence for a regulatory role of dolichyl phosphate in the transition from an intracellular to an extracellular IGF-1 pathway. Glycobiology. 1999;9(6):571-579.
11.
HelleSI. The insulin-like growth factor system in advanced breast cancer. Best Pract Res Clin Endocrinol Metab. 2004;18(1):67-79.
12.
FreierSWeissOEranM, et al. Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon. Gut. 1999;44(5):704-708.
13.
WeberMMFottnerCLiuSBJungMCEngelhardtDBarettonGB. Overexpression of the insulin-like growth factor I receptor in human colon carcinomas. Cancer. 2002;95(10):2086-2095.
14.
ShiratsuchiIAkagiYKawaharaA, et al. Expression of IGF-1 and IGF-1R and their relation to clinicopathological factors in colorectal cancer. Anticancer Res. 2011;31(7):2541-2545.
15.
XueyanZJiayuanSHuiminW, et al. IGF-1R and Bmi-1 expressions in lung adenocarcinoma and their clinicopathologic and prognostic significance. Tumor Biol. 2014;35(1):739-745.
16.
LaraPCBordonEReyAMorenoMLloretMHenríquez-HernándezLA. IGF-1R expression predicts clinical outcome in patients with locally advanced oral squamous cell carcinoma. Oral Oncol. 2011;47(7):615-619.
17.
FriedrichREHagelCBartel-FriedrichS. Insulin-like growth factor-1 receptor (IGF- 1R) in primary and metastatic undifferentiated carcinoma of the head and neck: a possible target of immunotherapy. Anticancer Res. 2010;30(5):1641-1643.
18.
MakiRG. Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J Clin Oncol. 2010;28(33):4985-4995.
19.
RosenzweigSAAtreyaHS. Defining the pathway to insulin-like growth factor system targeting in cancer. Biochem Pharmacol. 2010;80(8):1115-1124.
20.
YuHRohanT. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst. 2000;92(18):1472-1489.
21.
YulinYXuhongZJianS, et al. Expression and clinical significance of epidermal growth factor receptor and type 1 insulin-like growth factor receptor in nasopharyngeal carcinoma. Ann Otol Rhinol Laryngol. 2008;117(3):192-120.
22.
ZhangRXuGLLiY, et al. The role of insulin-like growth factor 1 and its receptor in the formation and development of colorectal carcinoma. J Int Med Res. 2013;41(4):1228-1235.
23.
LuHGuo-FengZYue-HuC, et al. Correlations of insulin-like growth factor I and insulin-like growth factor I receptor with the clinicopathological features and prognosis of patients with colon cancer. Jpn J Clin Oncol. 2016;46(12):1127-1134.
24.
Agulló-OrtuñoMTDíaz-GarcíaCVAgudo-LópezA, et al. Relevance of insulin-like growth factor 1 receptor gene expression as a prognostic factor in non-small-cell lung cancer. J Cancer Res Clin Oncol. 2015;141(1):43-53.
25.
KikuchiRSonobeMKobayashiM, et al. Expression of IGF1R is associated with tumor differentiation and survival in patients with lung adenocarcinoma. Ann Surg Oncol. 2012;19(suppl 3):412-420.
26.
GrykoMKiślukJCepowiczD, et al. Expression of insulin-like growth factor receptor type 1 correlate with lymphatic metastases in human gastric cancer. Pol J Pathol. 2014;65(2):135-140.
27.
MarisCD’HaeneNTre’pantAL, et al. IGF-IR: a new prognostic biomarker for human glioblastoma. Br J Cancer. 2015;113(5):729-737.
28.
GerritPSilviaGCordL, et al. IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows Arch. 2003;443(2):139-145.
29.
BjörnerSRosendahlA HSimonssonM, et al. Combined and individual tumor-specific expression of insulin-like growth factor-I receptor, insulin receptor and phosphor-insulin-like growth factor-I receptor/insulin receptor in primary breast cancer: implications for prognosis in different treatment groups. Oncotarget. 2017;8(6):9093-9107.
30.
M’hamdiHMokni BaizigNElAmine ELHadjO, et al. Usefulness of IGF-1 serum levels as diagnostic marker of nasopharyngeal carcinoma. Immunobiology. 2016;221(11):1304-1308.
31.
YavariKTaghikhaniMMaraghehMG, et al. Knockdown of IGF-IR by RNAi inhibits SW480 colon cancer cells growth in vitro. Arch Med Res. 2009;40(4):235-240.
32.
ScotlandiKManaraMCNicolettiG, et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res. 2005;65(9):3868-3876.
33.
LiHAdachiYYamamotoH, et al. Insulin-like growth factor-I receptor blockade reduces tumor angiogenesis and enhances the effects of bevacizumab for a human gastric cancer cell line, MKN45. Cancer. 2011;117(14):3135-3147.
34.
HewishMChauICunninghamD. Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. Recent Pat Anticancer Drug Discov. 2009;4(1):54-72.
35.
KalininaTBockhornMKaifiJT, et al. Insulin-like growth factor-1 receptor as a novel prognostic marker and its implication as a cotarget in the treatment of human adenocarcinoma of the esophagus. Int J Cancer. 2010;127(8):1931-1940.
36.
RailoMJvon SmittenKPekonenF. The prognostic value of insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients. Eur J Cancer. 1994;30A(3): 307-311.
37.
LudoviniVBellezzaGPistolaL, et al. High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. Ann Oncol. 2009;20(5):842-849.
38.
Henriquez-HernandezLALloretMPinarB, et al. BCL-2, in combination with MVP and IGF-1R expression, improves prediction of clinical outcome in complete response cervical carcinoma patients treated by radiochemotherapy. Gyneco Oncol. 2011;122(3):585-589.
39.
ValsecchiMEMcDonaldMBrodyJR, et al. Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma. Cancer. 2012;118(14):3484-3493.
40.
JiangYWangLGongW, et al. A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer. Clin Exp Metastasis. 2004;21(8):755-764.
41.
MatsubaraJYamadaYHirashimaY, et al. Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer. Clin Cancer Res. 2008;14(10):3022-3029.
42.
TeohNCDanYYSwisshelmK, et al. Defective DNA strand break repair causes chromosomal instability and accelerates liver carcinogenesis in mice. Hepatology. 2008;47(6):2078-2088.
43.
TurnerBCHafftyBGNarayanan, et al. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res. 1997;57(15):3079-3083.
44.
TezukaMWatanabeHNakamuraS, et al. Antiapoptotic activity is dispensable for insulin-like growth factor I receptor-mediated clonogenic radioresistance after γ-irradiation. Clin Cancer Res. 2001;7(10):3206-3214.
45.
NurwidyaFAndariniSTakahashiF, et al. Implications of insulin-like growth factor 1 receptor activation in lung cancer. Malays J Med Sci. 2016;23(3):9-21.
46.
CappuzzoFToschiLTalliniG, et al. Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Ann Oncol. 2006;17(7):1120-1127.
47.
FuPIbusukiMYamamotoY, et al. Quantitative determination of insulin-like growth factor 1 receptor mRNA in formalin-fixed paraffin-embedded tissues of invasive breast cancer. Breast Cancer. 2012;19(4):321-328.
48.
YoungLSDawsonCWClarkD, et al. Epstein–Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol. 1988;69(Pt 5):1051-1065.
49.
FahraeusRFuHLErnbergI, et al. Expression of Epstein–Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer. 1988;42(3):329-338.
50.
JeonYKLeeBYKimJE, et al. Molecular characterization of Epstein-Barr virus and oncoprotein expression in nasopharyngeal carcinoma in Korea. Head Neck. 2004;26(7):573-583.
51.
GulleyMLAminMBNichollsJM, et al. Epstein–Barr virus is detected in undifferentiated nasopharyngeal carcinoma but not in lymphoepithelioma-like carcinoma of the urinary bladder. Hum Pathol. 1995;26(11):1207-1214.
52.
LiXLiuXLiCY, et al. Recombinant adeno-associated virus mediated RNA interference inhibits metastasis of nasopharyngeal cancer cells in vivo and in vitro by suppression of Epstein-Barr virus encoded LMP-1. Int J Oncol. 2006;29(3):595-603.
53.
EndoKKondoSShacklefordJ, et al. Phosphorylated ezrin is associated with EBV latent membrane protein 1 in nasopharyngeal carcinoma and induces cell migration. Oncogene. 2009;28(14):1725-1735.
54.
ChenYPZhangWNChenL, et al. Effect of latent membrane protein 1 expression on overall survival in Epstein-Barr virus-associated cancers: a literature-based meta-analysis. Oncotarget. 2015;6(30):29311-29323.
55.
TworkoskiKRaab-TraubN. LMP1 promotes expression of insulin-like growth factor 1 (IGF1) to selectively activate IGF1 receptor and drive cell proliferation. J Virol. 2015;89(5):2590-2602.
56.
IwakiriDSheenTSChenJYHuangDPTakadaK. Epstein–Barr virus-encoded small RNA induces insulin-like growth factor 1 and supports growth of nasopharyngeal carcinoma-derived cell lines. Oncogene. 2005;24(10):1767-1773.
